CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer.

Walls, Gerard M; Oughton, Jamie B; Chalmers, Anthony J; Brown, Sarah; Collinson, Fiona; Forster, Martin D; Franks, Kevin N; Gilbert, Alexandra; Hanna, Gerard G; Hannaway, Nicola; Harrow, Stephen; Haswell, Tom; Hiley, Crispin T; Hinsley, Samantha; Krebs, Matthew; Murden, Geraldine; Phillip, Rachel; Ryan, Anderson J; Salem, Ahmed; Sebag-Montefoire, David; Shaw, Paul; Twelves, Chris J; Walker, Katrina; Young, Robin J; Faivre-Finn, Corinne; Greystoke, Alastair

Walls, Gerard M; Oughton, Jamie B; Chalmers, Anthony J; Brown, Sarah; Collinson, Fiona; Forster, Martin D; Franks, Kevin N; Gilbert, Alexandra; Hanna, Gerard G; Hannaway, Nicola; Harrow, Stephen; Haswell, Tom; Hiley, Crispin T; Hinsley, Samantha; Krebs, Matthew; Murden, Geraldine; Phillip, Rachel; Ryan, Anderson J; Salem, Ahmed; Sebag-Montefoire, David; Shaw, Paul; Twelves, Chris J; Walker, Katrina; Young, Robin J; Faivre-Finn, Corinne; Greystoke, Alastair.

Afiliación

Walls GM; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Northern Ireland, UK.
Oughton JB; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK.
Chalmers AJ; Institute of Cancer Sciences, University of Glasgow, Scotland, UK.
Brown S; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK.
Collinson F; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK.
Forster MD; Department of Oncology, UCL Cancer Institute, England, UK.
Franks KN; St James' Institute of Oncology, University of Leeds, England, UK.
Gilbert A; St James' Institute of Oncology, University of Leeds, England, UK.
Hanna GG; Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia.
Hannaway N; Newcastle University, Newcastle upon Tyne, England, UK.
Harrow S; The Beatson West of Scotland Cancer Centre, Glasgow, Scotland, UK.
Haswell T; Patient and Public Involvement Advocacy, UK.
Hiley CT; Department of Oncology, UCL Cancer Institute, England, UK.
Hinsley S; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK.
Krebs M; Institute of Cancer Sciences, University of Glasgow, Scotland, UK.
Murden G; Faculty of Biology, Medicine and Health, University of Manchester, England, UK.
Phillip R; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK.
Ryan AJ; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK.
Salem A; Oxford Institute for Radiation Oncology, University of Oxford, Oxford, England, UK.
Sebag-Montefoire D; The Christie NHS Foundation Trust/University of Manchester, Manchester, England, UK.
Shaw P; St James' Institute of Oncology, University of Leeds, England, UK.
Twelves CJ; Velindre University NHS Trust, Cardiff, Wales, UK.
Walker K; St James' Institute of Oncology, University of Leeds, England, UK.
Young RJ; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK.
Faivre-Finn C; Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, England, UK.
Greystoke A; Oxford Institute for Radiation Oncology, University of Oxford, Oxford, England, UK.

Clin Transl Radiat Oncol ; 25: 61-66, 2020 Nov.

Article en En | MEDLINE | ID: mdl-33072895

RESUMEN

Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for 'gold standard' treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.

Palabras clave

ATM, Ataxia telangiectasia mutated; ATR, Ataxia telangiectasia and Rad3 related; CRT, Chemoradiotherapy; CT, Computed tomography; CTCAE, Common terminology criteria for adverse events; CTRad, Clinical and Translational Radiotherapy Research Working Group; Continual reassessment method; DDRi, DNA damage response inhibitor; DLT, Dose limiting toxicity; DNA damage repair inhibitor; DNA, Deoxyribonucleic acid; DNA-PK, DNA-dependent protein kinase; ECOG, Eastern Cooperative Oncology Group; EORTC, European Organisation for Research and Treatment of Cancer; ICRU, International Commission on Radiation Units and Measurements; IMPs, Investigational medicinal products; LA, Locally advanced; MRC, Medical Research Council; NCRI, National Cancer Research Institute; NSCLC, Non-small cell lung cancer; Non-small cell lung cancer; PARP, Poly (ADP-ribose) polymerase; PET, Positron emission tomography; PFS, Progression free survival; PROMs, Patient-reported outcome measures; Platform trial; RECIST, Response evaluation criteria in solid tumours; RP2D, Recommended phase II dose; RT, Radiotherapy; SACT, Systemic anti-cancer therapy; SRC, Safety review committee; Sequential chemoradiotherapy; TNM, Tumour node metastasis; TiTE-CRM, Time to event continual reassessment method; cfDNA, Cell-free DNA

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google